Clinical trial
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 Administered Orally Once-Daily for 48 Weeks in Adult Patients With Cystic Fibrosis
NCT02443688 is registered in ClinicalTrials.gov with Celtaxsys, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 Administered Orally Once-Daily for 48 Weeks in Adult Patients With Cystic Fibrosis
- Lead sponsor
- Celtaxsys, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- October 30, 2015
- Completion date
- May 16, 2018
- Enrollment
- 200 (actual)
- Sites
- 75
Conditions
As the registry lists them; a condition with its own page is linked.